PNNT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
PNNT is not a good buy right now. The stock is in a confirmed downtrend (bearish moving-average stack and weakening MACD), insiders are aggressively selling, recent quarter fundamentals deteriorated sharply, and near-term pattern stats skew negative. With no Intellectia buy signals today and limited upside versus reduced Street targets, the risk/reward is unfavorable for an impatient buyer at $5.80.
Trend is bearish: SMA_200 > SMA_20 > SMA_5 confirms a sustained downtrend. Momentum is weakening as MACD histogram is negative (-0.019) and negatively expanding, suggesting downside pressure is increasing rather than stabilizing. RSI(6) at ~34.7 is near the lower end of neutral (not a clear oversold reversal signal), so there’s no strong technical evidence of a durable bounce. Key levels: immediate support S1 ~5.813 is essentially being tested at the current price (5.80); next support S2 ~5.709. Overhead resistance/pivot is ~5.981, then R1 ~6.149—price would need to reclaim ~5.98–6.15 to improve the short-term setup. Pattern-based projection also leans bearish (80% chance of -1.22% next day, -3.23% next week).
could act as a catalyst if credit performance and income metrics surprise positively. Open-interest skew (call-heavy) suggests some investors are positioned for upside, albeit without strong confirming volume.
Insiders are selling and the selling amount increased ~378% over the last month—strong negative sentiment from those closest to the business. Technicals remain bearish (downtrend MAs, worsening MACD) and statistical pattern projections skew to further declines over the next day/week. Analyst price targets were broadly cut recently, signaling tempered expectations. No supportive news flow in the last week to change sentiment. Elevated implied volatility indicates the market is pricing higher uncertainty/risk.
Latest reported quarter: 2025/Q4 showed sharp deterioration. Revenue fell to 17,158,000 (-57.59% YoY), net income dropped to -964,000 (down -105.25% YoY, turning more negative), EPS was -0.01 (-103.57% YoY), and gross margin fell to 41.36 (-40.61% YoY). This is a clear negative growth trend heading into the next earnings cycle, and it weakens the case for buying ahead of a turnaround confirmation.
Recent Street tone is mixed but trending more cautious due to price target cuts. Compass Point upgraded to Neutral from Sell but lowered PT to $5.50 (valuation-driven upgrade rather than improved fundamentals). JPMorgan kept Neutral and cut PT to $5.50. Keefe Bruyette kept Underperform and cut PT to $5.50. Truist kept Buy but cut PT to $7 and noted slower-than-expected rotation into higher-yielding assets, lowering 2026 earnings estimates. Wall Street pros: potential earnings tailwind if portfolio mix improves and valuation may look reasonable near $5.5–$5.8. Cons: large equity exposure, slower portfolio rotation, reduced earnings expectations, and multiple PT cuts clustered around $5.50—limiting near-term upside.
